CClinicalTrials.gg
CompletedNCT03447600DIVAUpdated Nov 6, 2020

Diet-Induced Variability in Appetite (DIVA)

An interventional study of Alternate Day Fasting and Continuous dietary restriction in Overweight and Obesity, sponsored by University of Leeds. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by University of Leeds · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The aim of this study is to test the hypothesis that dietary weight loss (WL) through alternate day fasting (ADF) will enhance appetite control, health markers and wellbeing following WL compared to standard daily calorie restriction (CR).

Read the detailed description

This is a proof of concept randomized controlled trial in which overweight/obese females will be randomised to a dietary weight loss intervention (ADF or CR) to achieve ≥5% WL. Behavioural measures of appetite control including ad libitum intake after a fixed meal, body composition, resting metabolic rate, measured physical activity and daily energy expenditure, sleep quality, hedonic food reward and eating behaviour traits will be assessed before, during and after the WL intervention in those who reach the target weight loss within 12 weeks. After weight loss phase, participants will be given standard healthy eating and physical activity advice for weight maintenance and body weight will be followed up after weight loss at 12 months.

02

Conditions studied

  • Overweight and Obesity

Browse trials for

03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Female participants aged between 18 and 55 years at the time of signing informed consent
  • BMI of 25.0 - 34.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Significant health problems which in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol
  • Currently enrolled in a weight loss programme or following a specific diet plan.
  • History of eating disorders including binge eating.
  • Taking any medication or supplements known to affect appetite or weight within the past month and/or during the study
  • Pregnant, planning to become pregnant or breastfeeding
  • History of anaphylaxis to food
  • Known food allergies or food intolerance
  • Smokers and those who have recently ceased smoking (\< 6 months)
  • BMI \< 24.9 kg/m2 or > 35 kg/m2
  • Volunteers having lost significant amount of weight in the previous 6 months (± 4kg)
  • Volunteers who exercise > 3 days per week or have significantly changed their physical activity patterns in the past 6 months or who intend to change them during the study
  • Participants receiving systemic or local treatment likely to interfere with evaluation of the study parameters
  • Participants who work in appetite or feeding related areas.
  • Participants who do shift work
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Alternate day fasting

    Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at \>/=5% weight loss which is an average of 12 weeks.

    Behavioral: Alternate Day Fasting

  • Active comparator
    Continuous caloric restriction

    Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at \>/=5% weight loss which is an average of 12 weeks.

    Behavioral: Continuous dietary restriction

Interventions

  • BehavioralAlternate Day Fasting

    25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.

  • BehavioralContinuous dietary restriction

    25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.

05

What researchers measure

Primary outcomes

  1. Change in energy intake from ad libitum lunch

    Measured changes in ad-libitum energy intake following consumption of formulated test meal in comparison to control

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

Secondary outcomes

  1. Change in Visual Analogue Scale (VAS) ratings of appetite

    Change in ratings of hunger, satiety, fullness and prospective food consumption before, after and between meals. Scale range is minimum 0 to maximum 100mm. A composite appetite score will be calculated from the average of scores on hunger, satiety, fullness and prospective food consumption scales. A higher score is considered a worse outcome.

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  2. Change in Control of Eating Questionnaire (CoEQ) scale scores

    21-item scale; subscales are average of relevant items; subscales are computed for dimensions of Craving Control, Craving for Savoury, Craving for Sweet, Positive Mood; minimum subscale score = 0, maximum subscale score = 100; higher values are better outcome for Craving Control and Positive Mood subscales; lower values are better outcome for Craving for Sweet and Craving for Savoury subscales.

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  3. Change in explicit liking of food from Leeds Food Preference Questionnaire

    Leeds Food Preference Questionnaire is a computer-based task with subscales scores for the 4 food categories high fat and sweet, high fat and non-sweet, low fat and sweet and low fat and non-sweet (minimum score = 0, maximum score = 100), Higher values for high fat food categories relative to low fat food categories considered worse outcome.

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  4. Change in explicit wanting of food from Leeds Food Preference Questionnaire scores

    Leeds Food Preference Questionnaire is a computer-based task with subscales scores for the 4 food categories high fat and sweet, high fat and non-sweet, low fat and sweet and low fat and non-sweet (minimum score = 0, maximum score = 100), Higher values for high fat food categories relative to low fat food categories considered worse outcome.

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  5. Change in relative preference of food from Leeds Food Preference Questionnaire scores

    Leeds Food Preference Questionnaire is a computer-based task with subscales scores for the 4 food categories high fat and sweet, high fat and non-sweet, low fat and sweet and low fat and non-sweet (minimum score = 0, maximum score = 48), Higher values for high fat food categories relative to low fat food categories considered worse outcome.

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  6. Change in implicit wanting of food from Leeds Food Preference Questionnaire scores

    Leeds Food Preference Questionnaire is a computer-based task with subscales scores for the 4 food categories high fat and sweet, high fat and non-sweet, low fat and sweet and low fat and non-sweet (minimum score = -100, maximum score = 100), Higher values for high fat food categories relative to low fat food categories considered worse outcome.

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  7. Change in VAS rating of palatability post lunch

    Change in ratings of pleasantness, desire to eat more and palatability after the lunch test meal

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  8. Change in fat mass

    Change in fat mass from iDXA/BodPod

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  9. Change in fat free mass

    Change in fat free mass from iDXA/BodPod

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  10. Change in resting metabolic rate

    Change in resting metabolic rate from indirect calorimetry

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

  11. Change in free-living physical activity

    Change in 7-day free-living physical activity from SenseWear Armband

    Time frame: week 0, week 3 and at study completion, an average of 12 weeks

06

Study locations

1 site
  • University of Leeds
    Leeds, West Yorkshire LS2 9JT, United Kingdom
07

References and documents

Publications

  • Beaulieu K, Casanova N, Oustric P, Turicchi J, Gibbons C, Hopkins M, Varady K, Blundell J, Finlayson G. Matched Weight Loss Through Intermittent or Continuous Energy Restriction Does Not Lead To Compensatory Increases in Appetite and Eating Behavior in a Randomized Controlled Trial in Women with Overweight and Obesity. J Nutr. 2020 Mar 1;150(3):623-633. doi: 10.1093/jn/nxz296. PubMed 31825067 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03447600
Lead sponsor
University of Leeds
Collaborators
University of Illinois at Chicago
Responsible party
Dr Graham Finlayson (Chair in Psychobiology, University of Leeds) — Principal investigator
First posted
Feb 27, 2018
Start date
Mar 1, 2018
Primary completion
Dec 12, 2018
Completion
Dec 12, 2018
Last update
Nov 6, 2020

Study contacts

Kristine Beaulieu, PhD
principal investigator · University of Leeds
Graham Finlayson, PhD
principal investigator · University of Leeds

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion